Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer

Aldilaijan, Abdulmohsin Fawzi; Kim, Young Il; Kim, Chan Wook; Yoon, Yong Sik; Park, In Ja; Lim, Seok‐Byung; Kim, Jihun; Ro, Jun-Soo; Kim, Jin Cheon

doi:10.1038/s41598-023-34855-9

Cited by 7 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CEA RNA-pulsed DC cancer vaccine used DCs to deliver an RNA encoding the CEA protein. This protein is often found on the surface of cancer cells ( 42 ). In this trial, patients underwent leukapheresis, and their cells were then exposed to recombinant human-GM-CSF and recombinant human-IL-4 in a medium to generate DCs.…”

Section: Crc Vaccines: Potential Targets Vaccine Types and Combinatio...mentioning

confidence: 99%

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Shebbo,

Binothman,

Darwaish

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer globally and presents a significant challenge owing to its high mortality rate and the limitations of traditional treatment options such as surgery, radiotherapy, and chemotherapy. While these treatments are foundational, they are often poorly effective owing to tumor resistance. Immunotherapy is a groundbreaking alternative that has recently emerged and offers new hope for success by exploiting the body’s own immune system. This article aims to provide an extensive review of clinical trials evaluating the efficacy of various immunotherapies, including CRC vaccines, chimeric antigen receptor T-cell therapies, and immune checkpoint inhibitors. We also discuss combining CRC vaccines with monoclonal antibodies, delve into preclinical studies of novel cancer vaccines, and assess the impact of these treatment methods on patient outcomes. This review seeks to provide a deeper understanding of the current state of CRC treatment by evaluating innovative treatments and their potential to redefine the prognosis of patients with CRC.

show abstract

Section: Crc Vaccines: Potential Targets Vaccine Types and Combinatio...mentioning

confidence: 99%

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Shebbo,

Binothman,

Darwaish

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The carcinoembryonic antigen (CEA) tumor-associated antigen is a membrane-anchored glycoprotein, overexpressed in 90–95% of colorectal primary tumors and respective metastases [ 20 ]. Moreover, CEA is frequently used for diagnosis and prognosis of CRC, constituting a promising target molecule for CRC therapy [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

scFv biofunctionalized nanoparticles to effective and safe targeting of CEA-expressing colorectal cancer cells

Silveira,

Martins,

Cruz

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the deadliest cancers worldwide, with the 5 year survival rate in metastatic cases limited to 12%. The design of targeted and effective therapeutics remains a major unmet clinical need in CRC treatment. Carcinoembryonic antigen (CEA), a glycoprotein overexpressed in most colorectal tumors, may constitute a promising molecule for generating novel CEA-targeted therapeutic strategies for CRC treatment. Here, we developed a smart nanoplatform based on chemical conjugation of an anti-CEA single-chain variable fragment (scFv), MFE-23, with PLGA-PEG polymers to deliver the standard 5-Fluorouracil (5-FU) chemotherapy to CRC cells. We confirmed the specificity of the developed CEA-targeted NPs on the internalization by CEA-expressing CRC cells, with an enhance of threefold in the cell uptake. Additionally, CEA-targeted NPs loaded with 5-FU induced higher cytotoxicity in CEA-expressing cells, after 24 h and 48 h of treatment, reinforcing the specificity of the targeted NPs. Lastly, the safety of CEA-targeted NPs loaded with 5-FU was evaluated in donor-isolated macrophages, with no relevant impact on their metabolic activity nor polarization. Altogether, this proof of concept supports the CEA-mediated internalization of targeted NPs as a promising chemotherapeutic strategy for further investigation in different CEA-associated cancers and respective metastatic sites.Authors: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author 1 Given name: [Maria José] Last name [Silveira]. Author 7 Given name: [Maria José] Last name [Oliveira]. Also, kindly confirm the details in the metadata are correctokAffiliations: Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary.ok Graphical Abstract

show abstract

“…Following birth, traces of CEA persist in colorectal tissue, yet its levels in the bloodstream are minimal. CEA has been identified as a prognostic biomarker for CRC due to its increased expression and secretion into the blood during invasion and tissue damage (28). Nevertheless, the relationship between CEA and oncofetal genes in terms of affinity and sensitivity remains unclear.…”

Section: Introductionmentioning

confidence: 99%

CEA-delta could be a biomarker of tumor phenotype, clinical stage, and chemotherapeutic response in rectal cancer with OCT4-positive cancer stem cells

Lozada-Martinez,

Bolaño-Romero,

Lambis-Anaya

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThere is very limited evidence on biomarkers for evaluating the clinical behavior and therapeutic response in rectal cancer (RC) with positive expression of cancer stem cells (CSCs).MethodsAn exploratory prospective study was conducted, which included fresh samples of tumor tissue from 109 patients diagnosed with primary RC. Sociodemographic, pathological and clinical characteristics were collected from medical records and survey. The OCT4 protein was isolated using the Western Blot technique. It was calculated the ΔCEA, ΔOCT4, and ΔOCT4/GUSB values by assessing the changes before and after chemotherapy, aiming to evaluate the therapeutic response.ResultsPatients had an average age of 69.9 years, with 55% (n=60) being male. Approximately 63.3% of the tumors were undifferentiated, and the most frequent staging classification was pathological stage III (n=64; 58.7%). Initial positive expression was observed in 77.1% of the patients (n=84), and the median ΔCEA was -1.03 (-3.82 - 0.84) ng/ml, with elevated levels (< -0.94 ng/ml) found in 51.4% of the subjects (n=56). Being OCT4 positive and having an elevated ΔCEA value were significantly associated with undifferentiated tumor phenotype (p=0.002), advanced tumor progression stage (p <0.001), and negative values of ΔOCT4 (p <0.001) (suggestive of poor therapeutic response) compared to those without this status.ConclusionThis study identified a significant and directly proportional association among the values of ΔCEA, ΔOCT4, and ΔOCT4/GUSB. These findings suggest that ΔCEA holds potential as a clinical biomarker for determining the undifferentiated tumor phenotype, advanced clinical stage, and poor therapeutic response in RC with CSCs positive expression.

show abstract

Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer

Cited by 7 publications

References 36 publications

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

scFv biofunctionalized nanoparticles to effective and safe targeting of CEA-expressing colorectal cancer cells

CEA-delta could be a biomarker of tumor phenotype, clinical stage, and chemotherapeutic response in rectal cancer with OCT4-positive cancer stem cells

Contact Info

Product

Resources

About